<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616694</url>
  </required_header>
  <id_info>
    <org_study_id>HMR4003B_4027</org_study_id>
    <nct_id>NCT00616694</nct_id>
  </id_info>
  <brief_title>Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy</brief_title>
  <acronym>ACTIVATE</acronym>
  <official_title>A Randomized Multicenter Parallel Group Study to Determine if Knowledge of Baseline Vertebral Fracture Prevalence (as Determined by Hologic IVA) and Bone Turnover Marker Determinations Improves Persistence With Actonel 5mg Daily Therapy in Subjects Receiving Chronic Glucocorticoid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of subject knowledge of their disease status on persistence in&#xD;
      subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment&#xD;
      of GIO.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether subject knowledge of baseline vertebral fracture prevalence and awareness of results of bone turnover marker (BTM)determinations would result in an increase in persistence with Actonel 5 mg daily therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate relationship between prevalence of vertebral fractures and duration of prior steroid therapy, amount of prior steroid therapy, and diagnosis of disease for which steroids were used</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the correlation between baseline vertebral fracture prevalence and subject persistence with Actonel 5 mg daily</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate influence of Actonel 5 mg on BTM determinations and bone mineral density(BMD) at study finish relative to baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">248</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actonel</intervention_name>
    <description>Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)</description>
    <other_name>Risedronate Sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a variety of rheumatologic, pulmonary, and skin conditions.&#xD;
&#xD;
          -  Subjects were to be on oral glucocorticoids with a mean daily dose of greater than or&#xD;
             equal to 5.0 mg prednisone (or its equivalent) and were expected (although not&#xD;
             required) to remain on a daily dose of greater than or equal to 5.0 mg prednisone (or&#xD;
             its equivalent) for 12 months after the study started.&#xD;
&#xD;
          -  Women must have been at least one year post-menopausal or surgically sterile.&#xD;
&#xD;
          -  Subjects must have had evaluable BMD site at the lumbar spine (LS) and proximal femur.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject's unwillingness to take Vitamin D, calcium supplements or study medication&#xD;
&#xD;
          -  A history of cancer: any history of cancer within the past 5 years. Relatively benign&#xD;
             skin malignancies, such as basal cell carcinoma or squamous cell carcinoma, are not an&#xD;
             exclusion if the subject has been in remission for at least 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  A history of hyperparathyroidism, hyperthyroidism or osteomalacia or other metabolic&#xD;
             bone disease within one year prior to enrollment&#xD;
&#xD;
          -  History of alcohol or drug dependence within one year of enrollment&#xD;
&#xD;
          -  A history of using any of the following medications within 6 months of starting study&#xD;
             drug: Estrogen or estrogen-related drugs (tamoxifen, raloxifene, tibolone); low dose&#xD;
             vaginal estrogen (estradiol &lt; 0.2 mg/day, estropipate &lt; 1.5 mg/day) will be&#xD;
             allowed,Anabolic steroids,Parathyroid hormone&#xD;
&#xD;
          -  A history of using any of the following medications within 1 month of starting study&#xD;
             drugor for more than 1 month within 6 months prior to study entry: Calcitonin,Vitamin&#xD;
             D supplements (&gt;1000 IU per day),Calcitriol (&gt;1.5mcg/week)&#xD;
&#xD;
          -  A history of using any of the following medications within 6 months of starting study&#xD;
             drug or for more than 14 days within 1 year prior to study entry: Any&#xD;
             bisphosphonate,Fluoride (&gt; 10 mg per day),Estrogen implant,Deflazacort&#xD;
&#xD;
          -  Have received a depot injection of &gt; 10,000 IU Vitamin D in the past 12 months&#xD;
&#xD;
          -  Have a documented history of an abnormal or allergic reaction to bisphosphonates&#xD;
&#xD;
          -  History of recurrent nephrolithiasis or a history of one episode of nephrolithiasis&#xD;
             within 5years of study entry&#xD;
&#xD;
          -  Severe renal impairment (creatinine clearance of &lt;30 mL/min)&#xD;
&#xD;
          -  Subjects on steroid therapy for transplantation&#xD;
&#xD;
          -  Subjects on oral glucocorticoids for &gt;8 weeks but &lt;6 months at screening&#xD;
&#xD;
          -  History of hypersensitivity to the investigational product or to drugs with similar&#xD;
             chemical structures&#xD;
&#xD;
          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major&#xD;
             systemic disease making implementation of the protocol or interpretation of the study&#xD;
             results difficult&#xD;
&#xD;
          -  Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>February 20, 2008</last_update_submitted>
  <last_update_submitted_qc>February 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

